We are live on ! Find out more
CANY

Caxton Associates (New York) Portfolio holdings

AUM $3.18B
1-Year Est. Return 54.49%
This Fund
S&P 500
This Quarter Est. Return
-18.82%
1 Year Est. Return
+54.49%
3 Year Est. Return
+73.91%
5 Year Est. Return
+212.89%
10 Year Est. Return
+632.2%
AUM
$1.03B
AUM Growth
-$200M
Cap. Flow
+$16M
Cap. Flow %
1.55%
Top 10 Hldgs %
58.26%
Holding
811
New
317
Increased
98
Reduced
90
Closed
269

Top Buys

Rank Stock Value
1
VAL icon
Valaris
VAL
+$24.3M
2
MRNA icon
Moderna
MRNA
+$9.63M
3
SLV icon
iShares Silver Trust
SLV
+$9.23M
4
TMUS icon
T-Mobile US
TMUS
+$9.02M
5
NE icon
Noble Corp
NE
+$6.74M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$107M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$29M
3
APTV icon
Aptiv
APTV
+$22.6M
4
MSFT icon
Microsoft
MSFT
+$20.8M
5
AMZN icon
Amazon
AMZN
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 23.31%
2 Consumer Discretionary 12.31%
3 Materials 12.15%
4 Industrials 5.19%
5 Financials 4.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EHC icon
276
Encompass Health
EHC
$12.4B
$499K 0.05%
+11,180
New +$574K
DOC icon
277
Healthpeak Properties
DOC
$14.8B
$498K 0.05%
+19,213
New +$582K
WWD icon
278
Woodward
WWD
$21.4B
$497K 0.05%
+5,378
New +$560K
AHT
279
Ashford Hospitality Trust
AHT
$21M
$495K 0.05%
+8,274
New +$558K
SBLK icon
280
Star Bulk Carriers
SBLK
$3.22B
$495K 0.05%
+19,798
New +$574K
LAMR icon
281
Lamar Advertising Co
LAMR
$16.3B
$492K 0.05%
+5,589
New +$567K
PTGX icon
282
Protagonist Therapeutics
PTGX
$9.44B
$485K 0.05%
+61,370
New +$742K
COO icon
283
Cooper Companies
COO
$14.5B
$480K 0.05%
+6,128
New +$542K
BCPC
284
Balchem Corp
BCPC
$5.72B
$480K 0.05%
+3,700
New +$463K
NICE icon
285
Nice
NICE
$5.97B
$474K 0.05%
2,465
+1,299
+111% +$263K
BFH icon
286
Bread Financial
BFH
$4.38B
$473K 0.05%
12,770
AGIO icon
287
Agios Pharmaceuticals
AGIO
$1.93B
$471K 0.05%
+21,228
New +$479K
CXW icon
288
CoreCivic
CXW
$3.19B
$471K 0.05%
+42,364
New +$512K
INMD icon
289
InMode
INMD
$880M
$468K 0.05%
+20,886
New +$549K
CBRL icon
290
Cracker Barrel
CBRL
$1.29B
$466K 0.05%
5,580
+2,025
+57% +$210K
GHC icon
291
Graham Holdings Company
GHC
$5.02B
$464K 0.05%
818
-255
-24% -$152K
NVRI icon
292
Enviri
NVRI
$620M
$464K 0.05%
+65,202
New +$588K
LPG icon
293
Dorian LPG
LPG
$1.96B
$463K 0.05%
+30,478
New +$483K
WTI icon
294
W&T Offshore
WTI
$518M
$463K 0.05%
+107,204
New +$603K
XRX icon
295
Xerox
XRX
$425M
$462K 0.04%
+31,133
New +$552K
MCHB
296
Mechanics Bancorp
MCHB
$3.68B
$459K 0.04%
13,244
-2,181
-14% -$87.8K
UHAL icon
297
U-Haul Holding Co
UHAL
$14.6B
$459K 0.04%
+9,600
New +$496K
IVE icon
298
iShares S&P 500 Value ETF
IVE
$49.8B
$456K 0.04%
+3,315
New +$489K
EQR icon
299
Equity Residential
EQR
$25.1B
$452K 0.04%
+6,254
New +$496K
EME icon
300
Emcor
EME
$36B
$451K 0.04%
+4,383
New +$469K

Similar funds

Caxton Associates (New York)'s Q2 2022 Portfolio in Review

As of Q2 2022, Caxton Associates (New York) held 811 positions worth $1.03B, down 16% from $1.23B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Caxton Associates (New York)'s Q2 2022 filing shows 317 new, 98 increased, 90 reduced and 269 closed positions. Its largest new stake was Valaris: 451,426 shares worth $19.1M. The largest sale was Tesla, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Materials.

  • Caxton Associates (New York)'s largest Q2 2022 buy was Valaris: 451,426 shares worth $19.1M.
  • Caxton Associates (New York) added most to Moderna in Q2 2022, an estimated $9.63M increase.
  • Caxton Associates (New York)'s biggest Q2 2022 reduction was Aptiv, cutting an estimated $22.6M.
  • Caxton Associates (New York) fully exited Tesla in Q2 2022, selling an estimated $107M.
  • Caxton Associates (New York)'s ten largest holdings make up 58% of its $1.03B portfolio in Q2 2022.
  • Caxton Associates (New York) opened 317 new positions and closed 269 in Q2 2022.
  • Caxton Associates (New York)'s portfolio value fell 16% quarter-over-quarter to $1.03B.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.